Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1989 Jan;57(1):174–179. doi: 10.1128/iai.57.1.174-179.1989

In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide.

G B Pier 1, D Thomas 1, G Small 1, A Siadak 1, H Zweerink 1
PMCID: PMC313063  PMID: 2491835

Abstract

We evaluated the in vitro opsonophagocytic killing activity of monoclonal human immunoglobulin G (IgG), IgM, and IgA specific for Pseudomonas aeruginosa lipopolysaccharide and the in vivo protective capacity in neutropenic mice of both monoclonal and purified polyclonal IgG, IgM, and IgA. Monoclonal IgM was efficacious in mediating opsonophagocytic killing only in conjunction with complement, whereas monoclonal IgG opsonic killing was potentiated by complement, and monoclonal IgA opsonic killing was independent of complement. These findings are similar to those previously reported for purified polyclonal IgM, IgG, and IgA. The monoclonal and polyclonal immunoglobulins had comparable 50% protective doses in neutropenic mice (range, 0.28 to 0.46 microgram per mouse). The protective activity of IgM in neutropenic mice was abolished by cobra venom factor treatment, whereas IgG and IgA maintained efficacy in cobra venom factor-treated mice. These data indicate that all three major human serum immunoglobulin isotypes have opsonophagocytic and protective activities against P. aeruginosa, with a critical role for complement in the function of IgM.

Full text

PDF
174

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barclay G. R., Yap P. L., McClelland D. B., Jones R. J., Roe E. A., McCann M. C., Micklem L. R., James K. Characterisation of mouse monoclonal antibodies produced by immunisation with a single serotype component of a polyvalent Pseudomonas aeruginosa vaccine. J Med Microbiol. 1986 Feb;21(1):87–90. doi: 10.1099/00222615-21-1-87. [DOI] [PubMed] [Google Scholar]
  2. Bjornson A. B., Michael J. G. Biological Activities of Rabbit Immunoglobulin M and Immunoglobulin G Antibodies to Pseudomonas aeruginosa. Infect Immun. 1970 Oct;2(4):453–461. doi: 10.1128/iai.2.4.453-461.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bjornson A. B., Michael J. G. Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. I. Interaction between immunoglobulins, heat-labile serum factors, and phagocytic cells in the killing of bacteria. Infect Immun. 1971 Oct;4(4):462–467. doi: 10.1128/iai.4.4.462-467.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blake M. S., Johnston K. H., Russell-Jones G. J., Gotschlich E. C. A rapid, sensitive method for detection of alkaline phosphatase-conjugated anti-antibody on Western blots. Anal Biochem. 1984 Jan;136(1):175–179. doi: 10.1016/0003-2697(84)90320-8. [DOI] [PubMed] [Google Scholar]
  5. Borowski R. S., Stock L. M., Schiller N. L. Development of an enzyme-linked immunosorbent assay for studying Pseudomonas aeruginosa cell surface antigens. J Clin Microbiol. 1984 Jun;19(6):736–741. doi: 10.1128/jcm.19.6.736-741.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Briles D. E., Claflin J. L., Schroer K., Forman C. Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature. 1981 Nov 5;294(5836):88–90. doi: 10.1038/294088a0. [DOI] [PubMed] [Google Scholar]
  7. Cryz S. J., Jr, Fürer E., Germanier R. Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model. Infect Immun. 1983 May;40(2):659–664. doi: 10.1128/iai.40.2.659-664.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dunn M. M., Kamp D. W. Pulmonary clearance of Pseudomonas aeruginosa in neutropenic mice. Effects of systemic immunization. Am Rev Respir Dis. 1987 Jun;135(6):1294–1299. doi: 10.1164/arrd.1987.135.6.1294. [DOI] [PubMed] [Google Scholar]
  9. Egan M. L., Pritchard D. G., Dillon H. C., Jr, Gray B. M. Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies. J Exp Med. 1983 Sep 1;158(3):1006–1011. doi: 10.1084/jem.158.3.1006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fanger M. W., Shen L., Pugh J., Bernier G. M. Subpopulations of human peripheral granulocyes and monocytes express receptors for IgA. Proc Natl Acad Sci U S A. 1980 Jun;77(6):3640–3644. doi: 10.1073/pnas.77.6.3640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pennington J. E., Small G. J., Lostrom M. E., Pier G. B. Polyclonal and monoclonal antibody therapy for experimental Pseudomonas aeruginosa pneumonia. Infect Immun. 1986 Oct;54(1):239–244. doi: 10.1128/iai.54.1.239-244.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pennington J. E., Small G. J. Passive immune therapy for experimental Pseudomonas aeruginosa pneumonia in the neutropenic host. J Infect Dis. 1987 May;155(5):973–978. doi: 10.1093/infdis/155.5.973. [DOI] [PubMed] [Google Scholar]
  13. Pier G. B., Ames P. Mediation of the killing of rough, mucoid isolates of Pseudomonas aeruginosa from patients with cystic fibrosis by the alternative pathway of complement. J Infect Dis. 1984 Aug;150(2):223–228. doi: 10.1093/infdis/150.2.223. [DOI] [PubMed] [Google Scholar]
  14. Pier G. B., Bennett S. E. Structural analysis and immunogenicity of Pseudomonas aeruginosa immunotype 2 high molecular weight polysaccharide. J Clin Invest. 1986 Feb;77(2):491–495. doi: 10.1172/JCI112328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pier G. B. Cross-protection by Pseudomonas aeruginosa polysaccharides. Infect Immun. 1982 Dec;38(3):1117–1122. doi: 10.1128/iai.38.3.1117-1122.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pier G. B. Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa. J Clin Invest. 1982 Feb;69(2):303–308. doi: 10.1172/JCI110453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pier G. B., Thomas D. M. Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa. J Infect Dis. 1983 Aug;148(2):206–213. doi: 10.1093/infdis/148.2.206. [DOI] [PubMed] [Google Scholar]
  18. Reynolds H. Y., Kazmierowski J. A., Newball H. H. Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages. J Clin Invest. 1975 Aug;56(2):376–385. doi: 10.1172/JCI108102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sawada S., Kawamura T., Masuho Y. Immunoprotective human monoclonal antibodies against five major serotypes of Pseudomonas aeruginosa. J Gen Microbiol. 1987 Dec;133(12):3581–3590. doi: 10.1099/00221287-133-12-3581. [DOI] [PubMed] [Google Scholar]
  20. Sawada S., Kawamura T., Masuho Y., Tomibe K. Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa. J Infect Dis. 1985 Nov;152(5):965–970. doi: 10.1093/infdis/152.5.965. [DOI] [PubMed] [Google Scholar]
  21. Schultz D. R., Miller K. D. Elastase of Pseudomonas aeruginosa: inactivation of complement components and complement-derived chemotactic and phagocytic factors. Infect Immun. 1974 Jul;10(1):128–135. doi: 10.1128/iai.10.1.128-135.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shigeoka A. O., Jensen C. L., Pincus S. H., Hill H. R. Absolute requirement for complement in monoclonal IgM antibody-mediated protection against experimental infection with type III group B streptococci. J Infect Dis. 1984 Jul;150(1):63–70. doi: 10.1093/infdis/150.1.63. [DOI] [PubMed] [Google Scholar]
  23. Stoll B. J., Pollack M., Young L. S., Koles N., Gascon R., Pier G. B. Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide. Infect Immun. 1986 Sep;53(3):656–662. doi: 10.1128/iai.53.3.656-662.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sturm S., Fortnagel P., Timmis K. N. Immunoblotting procedure for the analysis of electrophoretically-fractionated bacterial lipopolysaccharide. Arch Microbiol. 1984 Dec;140(2-3):198–201. doi: 10.1007/BF00454926. [DOI] [PubMed] [Google Scholar]
  25. Ward P. A., Hill J. H. C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J Immunol. 1970 Mar;104(3):535–543. [PubMed] [Google Scholar]
  26. Zweerink H. J., Gammon M. C., Hutchison C. F., Jackson J. J., Lombardo D., Miner K. M., Puckett J. M., Sewell T. J., Sigal N. H. Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa. Infect Immun. 1988 Aug;56(8):1873–1879. doi: 10.1128/iai.56.8.1873-1879.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Zweerink H. J., Gammon M. C., Hutchison C. F., Jackson J. J., Pier G. B., Puckett J. M., Sewell T. J., Sigal N. H. X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosa. Infect Immun. 1988 May;56(5):1209–1214. doi: 10.1128/iai.56.5.1209-1214.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES